Expression of secreted frizzled-related protein 1 and 3, T-cell factor 1 and lymphoid enhancer factor 1 in clear cell renal cell carcinoma by Nikuševa-Martić, Tamara et al.
     
 
Središnja medicinska knjižnica 
 
 
 
Nikuševa-Martić T., Šerman Lj., Zeljko M., Vidas Ž., Gašparov S., Zeljko 
H. M., Kosović M, Pećina-Šlaus N. (2013) Expression of secreted 
frizzled-related protein 1 and 3, T-cell factor 1 and lymphoid enhancer 
factor 1 in clear cell renal cell carcinoma. Pathology Oncology 
Research, 19 (3). pp. 545-51. ISSN 1219-4956 
 
 
http://www.springer.com/journal/12253 
 
http://link.springer.com/journal/12253 
 
http://dx.doi.org/10.1007/s12253-013-9615-3 
 
 
 
 
http://medlib.mef.hr/2247 
 
 
 
University of Zagreb Medical School Repository 
http://medlib.mef.hr/ 
   
 
 
 
 
 
Expression of Secreted Frizzled-Related Protein 1 and 3, T-cell Factor 1 and Lymphoid 
Enhancer Factor 1 in Clear Cell Renal Cell Carcinoma 
 
Tamara Nikuševa-Martić1, Ljiljana Šerman1 , Martina Zeljko2, Željko Vidas3, Slavko 
Gašparov4, Hrvojka Marija Zeljko2, Marin Kosović5,  Nives Pećina-Šlaus1 
 
 
 
1Department of Biology, School of Medicine, University of Zagreb, Šalata 3, HR-10000 
Zagreb, Croatia, e-mail: tmartic@mef.hr, tel.  
2Department of Internal Medicine, "Merkur" University Hospital, Zagreb, Croatia 
3Department of Urology, "Merkur" University Hospital, Zagreb, Croatia 
4Department of Clinical Pathology and Cytology, "Merkur" University Hospital, Zagreb, 
Croatia 
5Department of Physics and Biophysics, School of Medicine, University of Zagreb 
 
 
Corresponding author: Tamara Nikuševa Martić1 
1Department of Biology, School of Medicine,  
University of Zagreb, Šalata 3, HR-10000 Zagreb, Croatia,  
e-mail: tmartic@mef.hr, Phone: 00385 1 4566805, Fax. 00385 1 4590199 
 
 
 
 
Key words: SFRP1, SFRP3, TCF1, LEF1, cRCC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
 
Frequency and mortality of renal cell carcinoma (RCC) are increasing for decades. However, 
the molecular background of RCC tumorigenesis is still poorly understood. In current study 
we investigated the expression of TCF/LEF and SFRP family members (SFRP1 and SFRP3) 
to gain a better understanding of biological signaling pathways responsible for epidemiology 
and clinical parameters of clear cell RCC (cRCC). 
36 pairs of paraffin-embedded clear cRCC and adjacent nontumoral tissues samples using 
immunohistochemistry (IHC) were analyzed and compared with corresponding 
clinicopathological parameters. 
Immunohistochemistry indicated statistically significant decreased SFRP3 expression in 
tumor tissues but no consistency in SFRP1 expression in analyzed normal and tumor tissue. 
The TCF1 expression level was significantly weaker in normal tissue compared to tumor 
samples while LEF1 protein levels were significantly weaker in tumor tissue. 
To our knowledge, this is the first report on analysis of the expression of transcription factors 
TCF1 and LEF1 in clear cell renal cell carcinoma and their comparison with Wnt signal 
pathway antagonists belonging to SFRP family.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction  
 
Dysregulation of Wnt signaling is common in a variety of human malignancies. 
Therefore, to further explore the role of Wnt signaling in renal cell carcinoma, we 
investigated the expression of TCF/LEF transcription factors (TCF1 and LEF1) and SFRP 
family members (SFRP1 and SFRP3) using immunohistochemistry (IHC). All of these 
proteins play signaling roles as components of the Wnt signal transduction pathway. In most 
instances, constitutive signaling through the beta-catenin pathway involves activation of 
effector molecules or loss of tumor suppressor function downstream of Wnt ligands binding to 
its cell surface receptors. In the nucleus, beta-catenin relieves inhibition of transcription 
factors T-cell factor (TCF)/lymphoid enhancer factor (LEF) that was maintained by 
repressors, leading to transcription of target genes, such as c-myc, matrix metalloproteinase 
(MMP)-7, cyclin D1, etc. [1, 2]. LEF1 and TCF1 are members of the high mobility group 
(HMG) DNA binding protein family of transcription factors which consists of the following: 
Lymphoid Enhancer Factor 1 (LEF1), T Cell Factor 1 (TCF1, also known as TCF7), TCF3 
(also known as TCF7L1) and TCF4 (also known as TCF7L2) [3]. LEF1 and TCF1 were 
originally identified as important factors that act downstream in Wnt signaling regulating 
early lymphoid development [4]. LEF1 and TCF1 bind to Wnt response elements to provide 
docking sites for β-catenin, which translocate to the nucleus to promote the transcription of 
target genes upon activation of Wnt signaling [5]. LEF1 and TCF proteins are dynamically 
expressed during development and aberrant activation of the Wnt signaling pathway is 
involved in many types of cancers including colon cancer [6, 7]. 
 The secreted Frizzled-related proteins (SFRP) are the largest family of Wnt inhibitors. SFRPs 
decrease beta-catenin stabilization and promote cell death even in cells that have downstream 
mutations in the beta-catenin pathway. 
SFRP1 is a 35 kDa secreted glycoprotein that is a prototypical member of the SFRP family 
and has been reported to bind Wnt ligands and modulate their signaling activity [8, 9]. It acts 
as a biphasic modulator of Wnt signaling, counteracting Wnt-induced effects at high 
concentrations and promoting them at lower concentrations [9]. It is located in a chromosomal 
region (8p12- p11.1) that is frequently deleted in some cancers and is thought to harbor a 
tumor suppressor gene [10]. Among Wnt antagonist families, secreted frizzled-related protein 
(SFRP3) is generally thought to be an inhibitor of Wnt signaling in several cancers. 
 
 
Materials and methods  
 
Tumor specimen  
Samples of 36 renal cell carcinoma were collected from the Department of Pathology, 
University Hospital “Merkur”, Zagreb, Croatia. The tumor tissues were formalin fixed 
paraffin embedded. The patients had no family history of RCC tumors. All tumors were 
studied by pathologists and classified as Clear Cell Renal Cell Carcinoma according to the 
WHO criteria. The pathohistological classification, TNM stage and histopathological grading 
are shown in Table 1 
Twenty-five patients were male and 11 female. The age of patients varied from 30 to 
78 (mean age = 61.4 years). The mean age at diagnosis for males was 59.9, and for females 65 
years. 
The local Ethical Committee approved our study and patients gave their informed 
consent.  
 
Immunohistochemistry 
Immunohistochemistry was performed in order to establish the levels of expression 
and cellular localization of SFRP1, SFRP3, TCF1 and LEF1 proteins. The samples were 
formalin-fixed, paraffin embedded, and 4-µm thick sections were placed on Capillary gap 
microscope slides (DakoCytomation, Denmark). The sections were immunostained using the 
biotin–avidin–horseradish peroxidase method. Deparaffinized and rehydrated sections were 
microwaved in Dako Target Retrieval Solution (Dako Corporation, USA) three times for 5 
min at 800 W to unmask epitopes. To block endogenous peroxidase activity, we fixed the 
cells in methanol containing 3% H2O2. Non-specific binding was blocked by the application 
of normal mouse serum for 30 min in a humid chamber. Slides were blotted and primary 
antibodies at optimized dilutions were applied for 30 min at room temperature. The antibodies 
used for protein detection were: rabbit polyclonal anti-human SFRP1 (1:200), rabbit 
polyclonal anti-human SFRP3 (1:200), mouse monoclonal anti-human LEF1 (1:50) and for 
TCF1 (1:50) mouse monoclonal anti-human TCF1, all Santa Cruz Biotechnology, USA. After 
incubation, the slides were washed three times in phosphate-buffered saline/goat serum. 
Secondary LINK antibody was applied for 25 min. The washing was repeated, and the slides 
were incubated with streptavidin horseradish peroxidase for another 25 min. All chemicals 
were from DakoCytomation. Negative controls were samples that underwent same staining 
procedure with the exclusion of the primary antibodies. The analysis of the labeling was 
performed by two independent observers. 
 
Quantitative stereological analysis of numerical density (Nv) 
Randomly selected paraffin blocks were used for stereological analysis. Quantitative 
stereological analysis of numerical density (Nv) was performed by Nikon Alphaphot 
binocular light microscope (Nikon, Vienna, Austria) using Weibel’s multipurpose test system 
with 42 points (M 42) at magnification of 400x [12]. The area tested (At) was 0, 0837 mm
2. 
For each investigated group the orientation/pilot stereological measurement was carried out in 
order to define the number of fields to be tested [12]. The numerical density of positive cells 
was determined according to the point counting method [12]. Numerical density (Nv) was 
calculated by formula: Nv=N/At x D, where N is number of positive cells on tested area [13, 
14]. The mean tangential diameter (D) calculated by Ellipse3D for 100 cells were 0, 00917 
mm.  
Statistical Analysis 
Statistical analyses were performed using GraphPad Prism 5.01, (GraphPad Software, Inc., 
San Diego, CA, USA) and also Principal component analysis (PCA) was done using Matlab 
Software PLS Toolbox. The stereological data were evaluated by descriptive statistics. 
Distribution of the data was assessed by Kolomogorov-Smirnov test, Lilliefors test and 
Shapiro-Wilks W-test. Differences in numerical density of cells in investigated groups were 
analyzed with Kruskal-Wallis ANOVA. Statistical significance was set at p <0.05.  
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
In this study we analyzed 36 pairs of paraffin-embedded clear cell RCC and adjacent 
nontumoral tissues samples proved by Department of Pathology Clinical hospital Merkur 
Zagreb, Croatia. 
SFRP1 expression was observed in the nucleus and also occasionally in the cytoplasm. 
In renal tissue SFRP1 expression was found in tubules and glomeruli cells (Fig 1A, B).  
Interestingly, we did not find consistency in SFRP1 expression in analyzed normal and tumor 
tissue. Quantitative analysis revealed 51, 5% of analyzed nontumoral samples showed higher 
number of SFRP1 positive cells in comparison to tumor tissue. In 18, 2% of analyzed samples 
number of SFRP1 positive cells was approximately equal in both normal and tumor tissue 
whereas in 30, 3% of analyzed tumor samples number of SFRP1 positive cells was higher 
compared to adjacent normal tissue. The percentage of SFRP1 positive tumor tissues was not 
statistically significant correlated with the degree of tumor differentiation, nor with 
corresponding clinicopathological parameters. 
Subcellular localization of SFRP3 protein in renal tissue was observed in perinuclear 
region of tubules and glomeruli cells (Fig. 1C, D). We found statistically significant 
difference in number of SFRP3 positive cells between normal and tumor tissues (p< 0, 05) 
(Fig 2). The amount of SFRP3 protein expression in normal tissues was higher compared to 
the one observed in tumor tissue. Principal component analysis (PCA) performed with Matlab 
Software PLS Toolbox confirmed that SFPR3 expression contributes the most to the 
difference between normal and tumor tissue group (Fig 3 A, B). 
TCF1 expression was observed in the nucleus of tubules cells in a renal tissue (Fig. 
4A, B). Here also, we revealed statistically significant difference in number of TCF1 positive 
cells between normal and tumor tissues (p< 0, 05) (Fig. 2). The number of TCF1 positive cells 
was significantly minor in normal tissue compared to tumor samples.  
LEF1 protein was also detected in the nucleus of tubules and glomeruli cells in renal 
tissue (Fig. 4 C, D). We found statistically significant difference in analyzed number of LEF1 
positive cells between normal and tumor tissues (p< 0, 05) (Fig. 2). The amount of LEF1 
protein expression in normal tissues was higher compared to the one found in tumor tissue. 
We also notice negative correlations between SFRP3 and TCF1 (r= -0, 46), LEF1 and TCF1 
protein expressions, and positive correlation between SFRP3 and LEF1 protein expressions 
(r= 0, 46), (Fig. 5.) Mean values of numerical density (Nv) all four proteins are presented in 
Table 2. 
Discussion 
 
The SFRP family plays an important role in inhibition of the Wnt signaling pathway. 
The SFRP family show reduced expression in several types of carcinomas, which is 
associated with unfavorable clinical outcome [15]. 
As far as we know our study is a first attempt to analyze expression of transcription factors 
TCF1 and LEF1 in clear cell renal cell carcinoma and their comparison with Wnt signaling 
pathway antagonists belonging to SFRP family. SFRP1 competitively binds to Wnt 
molecules, thereby preventing their binding to the cognate Frizzled receptors and therefore act 
as a negative modulator of the Wnt pathway.  
Loss of SFRP1 has been reported in many human malignancies including RCC [16-19]. 
Levels of SFRP1 mRNA have been found to be reduced in human cRCC samples taken at 
different stages of the disease [16].  
In their recent study (2009) Saini et al., observed similar downregulation (mRNA level) of 
SFRP1 expression in primary RCC cell lines. However they also found augmented SFRP1 
expression in metastatic RCC cell lines [20]. 
Immunohistochemical data collected in the present study also indicate lower amount 
(although statistically insignificant) of SFRP1 expression in 51,5% of analyzed primary cRCC 
tumor tissue samples. Interestingly, in 30, 3% of primary cRCC analyzed in our study 
exhibited higher amount SFRP1 expression on a protein level compared to adjacent normal 
tissue. Since all of these primary tumor samples with higher amount SFRP1 expression were 
either obtained from patients with detected metastatic dissemination or had high Fuhrman 
grade we can speculate that registered augmentation of SFRP1 expression, later on  in 
metastatic tumor grades has its potential origine already in primary tumor tissue settings. 
Although in most studies SFRP1 is considered as tumor suppressor gene there are several 
reports that offer another view of the activity and regulation of secreted Wnt antagonists in 
different tumor tissues [19]. Notably, the SFRP1 gene was up regulated in prostate carcinoma 
derived from stromal cells and also in prostate carcinoma experimental model in which 
progressively advanced carcinoma cells acquired the expression of SFRP1 [21]. 
These results suggested that SFRP1 expression may be subjected to differential regulation 
during the renal cancer progression and metastasis. 
Human FRZB/SFRP3 has been mapped to human chromosome 2q31-33 [11]. SFRP3, 
another Wnt pathway antagonist, reduces activity of metalloproteinases and activation of β-
catenin and thus inhibits epithelial-mesenchymal transition (EMT) seen in several cancer 
types [22, 23]. We observed statistically significant decreased of the amount of SFRP3 protein 
expression in our total renal cancer clear cell tumors compared with normal kidney tissues. 
Using Principal component analysis (PCA) with Matlab Software PLS Toolbox we 
discovered SFPR3 expression pattern contributes the most to the difference between normal 
tissue control and tumor group. This data confirm the tumor-suppressing activities of 
FRZB/SFRP3. Hiroshi Hirata and his group [24] compared SFRP3 protein expression levels 
between normal kidney, primary renal cancer, and metastatic renal cancer tissues using tissue 
microarray. The percentage of samples expressing SFRP3 was lower in primary cancer tissues 
compared with normal kidney tissues. However, the percentage of samples expressing SFRP3 
was significantly higher in metastatic renal cancer tissues compared with primary renal cancer 
tissues. 
Wnt signaling controls the cell behavior by steering the transcriptional properties of 
DNA binding proteins belonging to the TCF/LEF1 family. In the absence of Wnt signaling 
TCF/LEF1 associate with corepresssors and blocks expression of Wnt target genes [25]. Since 
TCF/LEF1 factors cannot activate transcription on their own, they need co-activator, β-
catenin, which possesses multiple transactivating elements that can also operate independently 
of TCF/LEF1. There is a strict correlation between the ability of β-catenin to function in Wnt 
signaling and its ability to transactivate [26]. 
Since the discovery of TCF family, the functions of its members have been under immense 
investigation in the area of cancer biology. Although TCF1 plays an important role in 
developmental biology, its potential role in cancer progression still remains to be fully 
investigated. There have been no reports regarding expression of TCF1 and its isoforms in 
RCC. We revealed that amount of TCF1 expression was significantly weaker in analyzed 
normal tissue compared to tumor tissue.  
The human LEF1 gene is located at chromosome 4q23-25, the region not known to be 
involved in clear cell renal cell carcinoma. Nevertheless, we explored the possibility that 
changes in LEF1 protein level could contribute to the development of clear cell renal cell 
carcinoma. We observed statistically significant differences in amount of LEF1 expression 
between normal and tumor tissue. The amount of expression in normal tissues was higher as 
compared to the amount of expression in tumor tissue. This finding may indicate that LEF1 is 
not equally important as transcription factor in cRCC. Observed, statistically significant 
correlation between LEF1 and SFRP3 expression indicate a positive relationship of LEF1 and 
SFRP3 protein expression. Our result of statistically significant correlation between SFRP3 
and TCF1 expression could indicate that in given circumstances SFRP3 downregulation 
promotes TCF1 induced β-catenin transactivation of target genes, and that the negative 
correlation between LEF1 and TCF1 could suggest that in cRCC tumorigenesis exert 
differential functions.  
Reported expression of TCF1 and LEF 1 proteins in clear cell renal cell carcinoma is novel 
finding necessitating further research in order to establish their exact role in tumorigenesis of 
cRCC. 
 
Conclusion  
Current study represents the first report on TCF1 and LEF1 expression in clear cell 
renal cell carcinoma compared with Wnt signal pathway antagonists from the SFRP family. 
Observed differential expression of TCF1 and LEF1 transcription factors as well as SFRP3 in 
analyzed tumor and normal tissue samples indicates their involvement in cRCC 
tumorigenesis. However deciphering of their precise role in these processes requires 
additional studies involving among other more comprehensive methodological approaches 
and higher number of corresponding tissue samples. 
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Figure description 
 
Table 1. Clinicopathological parameters of 36 clear cell renal cell carcinomas analyzed in this 
study 
 
Patient 
number 
TNM classification Fuhrman age sex 
1. T3b, N0, M1 II 51 M 
2. T1b, Nx, Mx I 75 M 
3 T1b, Nx, Mx I 61 M 
4. T3, N0, M1 IV 72 M 
5. T1a, Nx, Mx II 57 M 
6. T1a, Nx, Mx II 67 F 
7. T1b, Nx, Mx II 52 F 
8. T3b, Nx, Mx III 73 F 
9. T1a, Nx, Mx II 30 M 
10. T1b, Nx, Mx III 43 M 
11. T1b, Nx, Mx II 47 M 
12. T1b, Nx, Mx II 78 M 
13. T1b, Nx, Mx III 64 M 
14. T3b, N0, M1 IV 56 M 
15. T1b, Nx, Mx II 62 F 
16 T2, Nx, Mx III 67 M 
17. T1a, Nx, Mx III 62 M 
18 T3, N0, Mx IV 59 M 
19. T2, Nx, Mx III 53 M 
20 T1a, Nx, Mx I 72 F 
21. T2, Nx, Mx III 42 M 
22. T1a, N0,  Mx I 46 F 
23. T2, Nx, Mx III 58 M 
24 T3b, N0, M1 II 64 M 
25. T3b, Nx, Mx IV 60 F 
26. T1a, Nx, Mx II 67 F 
27. T2, Nx, Mx II 61 M 
28. T1b, Nx, Mx II 68 F 
29 T1b, Nx, Mx II 64 M 
30. T1b, Nx, Mx II 70 F 
31. T1a, Nx, Mx II 77 M 
32 T1b, Nx, Mx III 75 M 
33. T1b, Nx, Mx I 78 F 
34 T2, Nx, Mx II 57 M 
35. T2, N2,  Mx II 60 M 
36. T3b, Nx, Mx II 65 M 
 
 
 
Table 2. Mean values and standard error of mean (SEM) for numerical densities (Nv) of 
SFRP3, TCF1, LEF1 and SFRP1 positive cells in tumors and adjacent control tissue. 
 
 SFRP3 
Nv (mm-3, ±SEM ) 
TCF1 
Nv (mm-3, ±SEM ) 
LEF1 
Nv (mm-3, ±SEM ) 
SFRP1 
Nv (mm-3, ±SEM ) 
Tumor 30212,8±1431,8 19452±1040,87 11736,5±545,547 37507,2±4250,5 
Control 62080,6±2105,59 5524,22±287,554 24405,2±926,49 42758,2±4609,43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Clear cell renal cell carcinoma immunohistochemically stained for protein 
expression of SFRP1 and SFRP3. Expression of SFRP1 protein in normal renal tissue (A) 
Expression of SFRP1 protein in cRCC (B) Expression of SFRP3 protein in normal renal 
tissue (C). Expression of SFRP3 protein in cRCC (D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Significant difference in average numerical density (Nv; mean values and standard 
error of the mean) of SFRP1, SFRP3, TCF1, LEF1 positive cells analyzed between tumor and 
adjacent nontumoral (control) tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Scores plot showing separation between tumour and control samples (A). Loadings 
plot showing parameters contribution to the separation of tumor and control (B). Comparing 
loadings with scores plot it can be seen that control samples have higher values of SFPR3 and 
LEF1 than tumor while tumor samples have higher values of TCF1 than control samples. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Clear cell renal cell carcinoma immunohistochemically stained for protein 
expression of TCF1 and LEF1. Expression of TCF1 protein in normal renal tissue (A) 
Expression of TCF1 protein in cRCC (B) Expression of LEF1 protein in normal renal tissue 
(C). Expression of LEF1 protein in cRCC (D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Correlation analysis between values of numerical density SFRP3, TCF1 and LEF1 
proteins. Both axes represent protein numerical density (Nv). 
 
 
